Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Adv Protein Chem Struct Biol. 2017 Oct 6;111:1–59. doi: 10.1016/bs.apcsb.2017.08.003

Fig. 3.

Fig. 3

Inhibition of heterodimerization of HER2:HER3 in HER2, HER3 transfected U2OS cells by compound 9 at different concentrations using enzyme fragment complementation assay (DiscoveRx). Dose–response curve for inhibition of HER2:HER3 heterodimerization by compound 9 in the presence of 0.3μM NRG1 (triangles). Control compound (CP) in the presence of 0.3μM NRG-1 (filled squares). Reproduced with permission from Kanthala, S., Banappagari, S., Gokhale, A., Liu, Y. Y., Xin, G., Zhao, Y., & Jois, S.(2015). Novel peptidomimetics for inhibition of HER2:HER3 heterodimerization in HER2-positive breast cancer. Chemical Biology & Drug Design, 85, 702–714. https://doi.org/10.1111/cbdd.12453. Copyright (2014) John Wiley and Sons.